Ibuprofen B. Braun (Ibuprofen)

Ibuprofen works by reversibly blocking the cyclooxygenase‑1 and cyclooxygenase‑2 enzymes, which are essential for converting arachidonic acid into prostaglandins. Lower prostaglandin levels reduce inflammation, decrease pain signal amplification, and lower the hypothalamic set‑point for temperature, producing analgesic, antipyretic, and anti‑inflammatory effects.

The specific dose and infusion rate of Ibuprofen B. Braun are determined by the prescribing clinician based on the patient’s age, weight, clinical condition, and therapeutic goals. Healthcare professionals follow local guidelines and product labeling to set the appropriate regimen.

Safety data for intravenous ibuprofen in pregnancy and lactation are limited, and the product’s pregnancy category is listed as unknown. Clinicians should weigh potential benefits against risks and consider alternative therapies when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed), and import documentation.

Ibuprofen B. Braun offers a non‑selective COX inhibition profile similar to other injectable NSAIDs such as ketorolac, but it may have a slightly lower risk of renal toxicity at comparable doses. Choice of agent depends on the clinical scenario, patient comorbidities, and physician preference.

The product must be stored refrigerated between 2 °C and 8 °C, protected from light, and should never be frozen or shaken. Prior to administration, inspect the solution for particulate matter and ensure the vial is within its expiry date.

Ibuprofen B. Braun is given as an intravenous infusion. The vial is diluted with an appropriate compatible solution and administered over the recommended time period, typically 15–30 minutes, under aseptic conditions by qualified healthcare personnel.

Serious risks include gastrointestinal bleeding or ulceration, acute renal failure, severe hypersensitivity reactions such as anaphylaxis, and rare but life‑threatening skin reactions like Stevens‑Johnson syndrome. Patients should be monitored closely for signs of these events.

Ibuprofen B. Braun is contraindicated in patients with known hypersensitivity to ibuprofen or other NSAIDs, active gastrointestinal bleeding or ulceration, severe renal impairment, and those who have experienced previous severe allergic reactions to injectable NSAIDs.